Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIA study of aliskiren added to ramipril with volume intervention in non-diabetic nephropathy
NL-OMON36542Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of aliskiren, ramipril and hydrochlorothiazide in Non-diabetic nephropathy (2 arms), sponsored by Novartis. Primary endpoint: Proteinuria. Started Jan 2011; status: active, not recruiting.
02
Drugs
aliskirenramiprilhydrochlorothiazide
03
Conditions
Non-diabetic nephropathy
Beyond the preview
Go deeper on NL-OMON36542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36542.